New RA Drugs Show Promise
Pipeline Is Packed With New Rheumatoid Arthritis Treatments
June 15, 2007 (Barcelona, Spain) --The pipeline is bursting with promising new treatments for rheumatoid arthritis (RA), say researchers.
RA is an autoimmune disease in which the body attacks its own joints, resulting in pain and inflammation.
Though the advent of medications known as biologic agents have revolutionized the treatment of RA, the next generation also may have a lot to offer the 2.1 million people who live with rheumatoid arthritis, according to experts speaking here at the annual meeting of the European League Against Rheumatism (EULAR) in Barcelona, Spain.
Biologic agents such as Enbrel, Humira, Kineret, and Remicade reduce inflammation by blocking substances that cause or worsen joint inflammation in RA. They copy the effects of chemicals made by the immune system, which block inflammatory substances such as TNF (tumor necrosis factor).
“The pipeline is rich and there are a lot of new possibilities,” Iain McInnes, MRCP, PhD, a professor of experimental medicine and rheumatology at the University of Glasgow in Scotland, tells WebMD. “The challenge is to work out which ones to use and when.”
New Rheumatoid Arthritis Drugs
Cimzia. In people with RA who do not respond well to treatment with an older drug called methotrexate, adding the experimental TNF-blocker Cimzia may do the trick, says Edward Keystone, MD, a rheumatologist at the University of Toronto in Ontario.
People in the study who took the Cimzia with methotrexate were more likely to feel better than those who took methotrexate alone. What’s more, people taking Cimzia improved quicker than what has traditionally been seen with the other TNF-blockers on the market such as Enbrel, Remicade, or Humira.
This drug has a different chemical structure than the currently available anti-TNF drugs, which allows it to remain active in the body for longer periods of time and may allow it to go directly to the inflamed joint.
Among other potential perks, it may be cheaper to manufacture than other TNF-blockers. It also works faster and appears to be safer for women of childbearing age, which could put it ahead of the pack, he says.